Advisor Group Holdings, Inc. Chemo Centryx, Inc. Transaction History

Advisor Group Holdings, Inc.

$42.2 Billion
Q3 2024

Shares

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 14, 2022	SELL	$22.17 - $51.8 $52,986 - $123,802	-2,390 Reduced 43.3%	3,130 $163,000
Q2 2022 Aug 10, 2022	SELL	$15.36 - $27.51 $15,974 - $28,610	-1,040 Reduced 15.85%	5,520 $137,000
Q1 2022 May 04, 2022	BUY	$22.22 - $39.12 $24,419 - $42,992	1,099 Added 20.12%	6,560 $212,000
Q3 2021 Nov 05, 2021	SELL	$13.18 - $19.83 $15,341 - $23,082	-1,164 Reduced 17.57%	5,461 $94,000
Q2 2021 Aug 02, 2021	BUY	$9.59 - $50.88 $55,257 - $293,170	5,762 Added 667.67%	6,625 $88,000
Q1 2021 May 13, 2021	BUY	$49.53 - $68.4 $396 - $547	8 Added 0.94%	863 $45,000
Q4 2020 Feb 10, 2021	BUY	$47.25 - $65.16 $36,193 - $49,912	766 Added 860.67%	855 $52,000
Q3 2020 Nov 12, 2020	BUY	$46.35 - $61.69 $4,125 - $5,490	89 New	89 $5,000
Q2 2020 Aug 14, 2020	SELL	$38.58 - $65.07 $44,791 - $75,546	-1,161 Closed	0 $0
Q1 2020 May 18, 2020	BUY	$32.73 - $50.78 $37,999 - $58,955	1,161 New	1,161 $47,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.